Hot Features
Premium
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Period:
Draw Mode:
| Volume | 11,077 |
|
|||||
| News | - | ||||||
| Day High | 3.185 | Low High |
|||||
| Day Low | 3.06 | ||||||
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| MEI Pharma Inc | MEIP | NASDAQ | Common Stock |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 3.06 | 17:47:24 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 3.08 | 3.06 | 3.185 | 3.06 | 3.06 |
| Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 156 | 11,077 | US$ 3.14 | US$ 34,775 | - | 3.01 - 7.97 |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| 15:00:14 | seq | 100 | US$ 3.08 | USD |
MEI Pharma Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 20.39M | 6.66M | - | 48.82M | -31.84M | -4.78 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
MEI Pharma News
| Date | Time | Source | News Article |
|---|---|---|---|
| 4/11/2024 | 07:02 | Business Wire | MEI Pharma Board of Directors Aligns on Strategy to Advance.. |
| 4/11/2024 | 07:00 | Business Wire | MEI Pharma Reports Initial Data from Clinical Study.. |
| 4/10/2024 | 07:00 | Business Wire | MEI Pharma to Present at the Stifel 2024 Virtual Targeted.. |
| 3/26/2024 | 07:00 | Business Wire | MEI Pharma Reports Update from Clinical Study Evaluating.. |
| 2/28/2024 | 23:15 | Edgar (US Regulatory) | Form EFFECT - Notice of Effectiveness |
| 2/21/2024 | 15:00 | Edgar (US Regulatory) | Form 8-K - Current report |
| 2/20/2024 | 16:33 | Edgar (US Regulatory) | Form S-3 - Registration statement under Securities Act of.. |
| 2/13/2024 | 16:05 | Edgar (US Regulatory) | Form 8-K - Current report |
| 2/13/2024 | 16:05 | Business Wire | MEI Pharma Reports Second Quarter Fiscal Year 2024 Results.. |
| 1/17/2024 | 15:00 | Edgar (US Regulatory) | Form 8-K - Current report |
| 1/16/2024 | 16:00 | Business Wire | MEI Pharma to Present Design of Ongoing Clinical Study.. |
| 12/26/2023 | 16:00 | Edgar (US Regulatory) | Form 8-K - Current report |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical MEIP Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 3.26 | 3.26 | 3.01 | 3.07 | 10,072 | -0.20 | -6.13% |
| 1 Month | 4.01 | 4.06 | 3.01 | 3.42 | 13,693 | -0.95 | -23.69% |
| 3 Months | 4.49 | 4.97 | 3.01 | 3.92 | 21,003 | -1.43 | -31.85% |
| 6 Months | 6.97 | 7.8734 | 3.01 | 5.65 | 35,295 | -3.91 | -56.10% |
| 1 Year | 5.10 | 7.97 | 3.01 | 6.39 | 43,287 | -2.04 | -40.00% |
| 3 Years | 72.00 | 73.20 | 3.01 | 19.37 | 1,261,538 | -68.94 | -95.75% |
| 5 Years | 62.80 | 91.50 | 3.01 | 31.94 | 1,118,129 | -59.74 | -95.13% |
MEI Pharma Description
| MEI Pharma Inc is focused on the clinical development of novel therapies for cancer. The company's clinical drug candidate includes Pracinostat, an orally available histone deacetylase inhibitor for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Its clinical development portfolio also includes Zandelisib, an oral inhibitor of phosphatidylinositide 3-kinase delta for the treatment of patients with recurrent chronic lymphocytic leukemia or follicular non-Hodgkin's lymphoma; and ME-344, an isoflavone-based mitochondrial inhibitor for the treatment of HER2-negative breast cancer and Pracinostat, an oral histone deacetylase inhibitor. Geographically, all the business activities function through the region of the United States. |
